Literature DB >> 30012752

Ambroxol Induces Autophagy and Potentiates Rifampin Antimycobacterial Activity.

Seong Won Choi1, Yuexi Gu1,2, Ryan Scott Peters1,2, Padmini Salgame3, Jerrold J Ellner4, Graham S Timmins5, Vojo Deretic6,2.   

Abstract

Host-directed therapy in tuberculosis is a potential adjunct to antibiotic chemotherapy directed at Mycobacterium tuberculosis Ambroxol, a lead compound, emerged from a screen for autophagy-inducing drugs. At clinically relevant doses, ambroxol induced autophagy in vitro and in vivo and promoted mycobacterial killing in macrophages. Ambroxol also potentiated rifampin activity in a murine tuberculosis model.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Mycobacterium tuberculosis; autophagy

Mesh：

Substances：

Year:  2018        PMID： 30012752      PMCID： PMC6125555          DOI： 10.1128/AAC.01019-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Identification of CYP3A4 as the predominant isoform responsible for the metabolism of ambroxol in human liver microsomes.

Authors:  N Ishiguro; C Senda; W Kishimoto; K Sakai; Y Funae; T Igarashi
Journal:  Xenobiotica       Date:  2000-01       Impact factor: 1.908

2.  Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.

Authors:  A H Diacon; R F Patientia; A Venter; P D van Helden; P J Smith; H McIlleron; J S Maritz; P R Donald
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

3.  Minimum inhibitory concentration distributions for Mycobacterium avium complex-towards evidence-based susceptibility breakpoints.

Authors:  Thomas Schön; Erja Chryssanthou
Journal:  Int J Infect Dis       Date:  2017-01-06       Impact factor: 3.623

4.  Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain.

Authors:  Wolfram Gaida; Klaus Klinder; Kirsten Arndt; Thomas Weiser
Journal:  Neuropharmacology       Date:  2005-09-21       Impact factor: 5.250

5.  The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.

Authors:  Jakko van Ingen; Eric F Egelund; Adrah Levin; Sarah E Totten; Martin J Boeree; Johan W Mouton; Rob E Aarnoutse; Leonid B Heifets; Charles A Peloquin; Charles L Daley
Journal:  Am J Respir Crit Care Med       Date:  2012-06-28       Impact factor: 21.405

6.  Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection.

Authors:  Maurizio Renna; Catherine Schaffner; Karen Brown; Shaobin Shang; Marcela Henao Tamayo; Krisztina Hegyi; Neil J Grimsey; David Cusens; Sarah Coulter; Jason Cooper; Anne R Bowden; Sandra M Newton; Beate Kampmann; Jennifer Helm; Andrew Jones; Charles S Haworth; Randall J Basaraba; Mary Ann DeGroote; Diane J Ordway; David C Rubinsztein; R Andres Floto
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

7.  High-dose Oral Ambroxol for Early Treatment of Pulmonary Acute Respiratory Distress Syndrome: an Exploratory, Randomized, Controlled Pilot Trial.

Authors:  Arun K Baranwal; Aparna S Murthy; Sunit C Singhi
Journal:  J Trop Pediatr       Date:  2015-06-30       Impact factor: 1.165

8.  Perioperative Lung Protection Provided by High-Dose Ambroxol in Patients with Lung Cancer.

Authors:  Xin Wang; Lei Wang; Huayong Wang; Hao Zhang
Journal:  Cell Biochem Biophys       Date:  2015-11       Impact factor: 2.194

9.  Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease.

Authors:  Gustavo H B Maegawa; Michael B Tropak; Justin D Buttner; Brigitte A Rigat; Maria Fuller; Deepangi Pandit; Liangiie Tang; Gregory J Kornhaber; Yoshitomo Hamuro; Joe T R Clarke; Don J Mahuran
Journal:  J Biol Chem       Date:  2009-07-03       Impact factor: 5.157

10.  High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Authors:  Martin J Boeree; Norbert Heinrich; Rob Aarnoutse; Andreas H Diacon; Rodney Dawson; Sunita Rehal; Gibson S Kibiki; Gavin Churchyard; Ian Sanne; Nyanda E Ntinginya; Lilian T Minja; Robert D Hunt; Salome Charalambous; Madeleine Hanekom; Hadija H Semvua; Stellah G Mpagama; Christina Manyama; Bariki Mtafya; Klaus Reither; Robert S Wallis; Amour Venter; Kim Narunsky; Anka Mekota; Sonja Henne; Angela Colbers; Georgette Plemper van Balen; Stephen H Gillespie; Patrick P J Phillips; Michael Hoelscher
Journal:  Lancet Infect Dis       Date:  2016-10-26       Impact factor: 25.071
View more
  13 in total

Review 1.  Repositioning rifamycins for Mycobacterium abscessus lung disease.

Authors:  Uday S Ganapathy; Véronique Dartois; Thomas Dick
Journal:  Expert Opin Drug Discov       Date:  2019-06-14       Impact factor: 6.098

Review 2.  Enhancement of lung levels of antibiotics by ambroxol and bromhexine.

Authors:  Vojo Deretic; Graham S Timmins
Journal:  Expert Opin Drug Metab Toxicol       Date:  2019-02-07       Impact factor: 4.481

Review 3.  Therapeutic modulation of autophagy: which disease comes first?

Authors:  Maria Chiara Maiuri; Guido Kroemer
Journal:  Cell Death Differ       Date:  2019-02-06       Impact factor: 15.828

Review 4.  Autophagy: A new strategy for host-directed therapy of tuberculosis.

Authors:  Seungwha Paik; Jin Kyung Kim; Chaeuk Chung; Eun-Kyeong Jo
Journal:  Virulence       Date:  2018-11-02       Impact factor: 5.882

5.  Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19.

Authors:  Giovanni Bocci; Steven B Bradfute; Chunyan Ye; Matthew J Garcia; Jyothi Parvathareddy; Walter Reichard; Surekha Surendranathan; Shruti Bansal; Cristian G Bologa; Douglas J Perkins; Colleen B Jonsson; Larry A Sklar; Tudor I Oprea
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-14

Review 6.  Autophagy in inflammation, infection, and immunometabolism.

Authors:  Vojo Deretic
Journal:  Immunity       Date:  2021-03-09       Impact factor: 31.745

Review 7.  Something Old, Something New: Ion Channel Blockers as Potential Anti-Tuberculosis Agents.

Authors:  Steven C Mitini-Nkhoma; Elizabeth T Chimbayo; David T Mzinza; David V Mhango; Aaron P Chirambo; Christine Mandalasi; Agness E Lakudzala; Dumizulu L Tembo; Kondwani C Jambo; Henry C Mwandumba
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

Review 8.  Autophagy Induction as a Host-Directed Therapeutic Strategy against Mycobacterium tuberculosis Infection.

Authors:  Harresh Adikesavalu; Radha Gopalaswamy; Ashok Kumar; Uma Devi Ranganathan; Sivakumar Shanmugam
Journal:  Medicina (Kaunas)       Date:  2021-05-23       Impact factor: 2.430

Review 9.  The Macrophage Response to Mycobacterium tuberculosis and Opportunities for Autophagy Inducing Nanomedicines for Tuberculosis Therapy.

Authors:  Retsepile E Maphasa; Mervin Meyer; Admire Dube
Journal:  Front Cell Infect Microbiol       Date:  2021-02-08       Impact factor: 5.293

10.  Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2.

Authors:  Myasar Alkotaji
Journal:  Int J Antimicrob Agents       Date:  2020-10-10       Impact factor: 15.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.